BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors
The major provider of gene-edited lab rodents gets the nod for a Hong Kong listing after abandoning a plan to float shares on Shanghai’s STAR Market Key Takeaways: Gene-edited lab…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
- Waiting for new industry dawn, SolarSpace turns to IPO for warmth
